175 related articles for article (PubMed ID: 9580870)
21. Beta interferon and multiple sclerosis: why the fuss?
Mumford CJ
QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
[No Abstract] [Full Text] [Related]
22. Patients' views of explicit rationing: what are the implications for health service decision-making?
Devlin N; Appleby J; Parkin D
J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
[TBL] [Abstract][Full Text] [Related]
23. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
Napier JC; Francis R; Wright G
BMJ; 2003 May; 326(7400):1212. PubMed ID: 12775633
[No Abstract] [Full Text] [Related]
24. Will public health survive QALYs?
Heller JG
Can J Clin Pharmacol; 2002; 9(1):5-6. PubMed ID: 11919640
[No Abstract] [Full Text] [Related]
25. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
Curtiss FR
J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
[No Abstract] [Full Text] [Related]
26. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis.
Kobelt G; Jönsson L; Henriksson F; Fredrikson S; Jönsson B
Int J Technol Assess Health Care; 2000; 16(3):768-80. PubMed ID: 11028132
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of Avonex (interferon beta-Ia) in patients following a single demyelinating event.
Iskedjian M; Walker JH; Gray T; Vicente C; Einarson TR; Gehshan A
Mult Scler; 2005 Oct; 11(5):542-51. PubMed ID: 16193892
[TBL] [Abstract][Full Text] [Related]
28. Rebif offers another option for treating multiple sclerosis.
Ryan M
J Am Pharm Assoc (Wash); 2002; 42(6):889-91. PubMed ID: 12482017
[No Abstract] [Full Text] [Related]
29. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
30. [Disease-modifying treatment of MS--progress with complications].
Fagius J
Lakartidningen; 2003 Mar; 100(13):1164, 1167-8. PubMed ID: 12705166
[No Abstract] [Full Text] [Related]
31. Interferon beta produces only small benefits in multiple sclerosis.
McKee L
BMJ; 1998 May; 316(7142):1410. PubMed ID: 9616008
[No Abstract] [Full Text] [Related]
32. [Cost-utility analysis of relapsing-remitting multiple sclerosis treatment with azathioprine or interferon beta in Spain].
Rubio-Terrés C; Domínguez-Gil Hurlé A
Rev Neurol; 2005 Jun 16-30; 40(12):705-10. PubMed ID: 15973634
[TBL] [Abstract][Full Text] [Related]
33. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
[TBL] [Abstract][Full Text] [Related]
34. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-beta and glatiramer acetate for multiple sclerosis.
Tappenden P; Chilcott JB; Eggington S; Oakley J; McCabe C
Health Technol Assess; 2004 Jun; 8(27):iii, 1-78. PubMed ID: 15215017
[TBL] [Abstract][Full Text] [Related]
35. Cost utility of drugs for multiple sclerosis. Methods used don't calculate true benefit.
Richards R; Burls A; Payne N
BMJ; 2000 May; 320(7247):1475; author reply 1475-6. PubMed ID: 10877570
[No Abstract] [Full Text] [Related]
36. Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Castelli-Haley J; Oleen-Burkey M; Lage MJ; Johnson KP
Adv Ther; 2008 Jul; 25(7):658-73. PubMed ID: 18641926
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population.
Tappenden P; McCabe C; Chilcott J; Simpson E; Nixon R; Madan J; Fisk JD; Brown M
Value Health; 2009; 12(5):657-65. PubMed ID: 19508662
[TBL] [Abstract][Full Text] [Related]
38. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.
Curkendall SM; Wang C; Johnson BH; Cao Z; Preblick R; Torres AM; Knappertz V; Gondek K
Clin Ther; 2011 Jul; 33(7):914-25. PubMed ID: 21684600
[TBL] [Abstract][Full Text] [Related]
39. All people with MS have a right to be treated.
Scott H
Br J Nurs; 2000 Jul 13-26; 9(13):816. PubMed ID: 11261052
[No Abstract] [Full Text] [Related]
40. Serono pays $44m to settle promotion of multiple sclerosis drug.
Tanne JH
BMJ; 2011 May; 342():d2922. PubMed ID: 21558361
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
